Artículos por temáticas

What are the prospects of slowing the progression of Alzheimer's disease?

Palmer AM.

Drug Discov Today. 2012 Nov;17(21-22):1157-9. doi: 10.1016/j.drudis.2012.09.009. Epub 2012 Oct 2.

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group.

Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474-4422(12)70206-5. Epub 2012 Sep 6.

The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

Bales KR.

Expert Opin Drug Discov. 2012 Apr;7(4):281-97. doi: 10.1517/17460441.2012.666234. Epub 2012 Feb 23.

A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment

Amanzio M, Benedetti F, Vase L.

Int Psychogeriatr. 2012 May;24(5):698-707. doi: 10.1017/S1041610211002420. Epub 2012 Jan 4.

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia

Allegri RF, Guekht A.

Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721.

Withdrawal syndrome after donepezil cessation in a patient with dementia

Bidzan L, Bidzan M.

Neurol Sci. 2012 Dec;33(6):1459-61. doi: 10.1007/s10072-012-0938-8. Epub 2012 Jan 15.

Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools

Di Carlo M, Giacomazza D, San Biagio PL.

J Phys Condens Matter. 2012 Jun 20;24(24):244102. doi: 10.1088/0953-8984/24/24/244102. Epub 2012 May 18.

Recent preclinical evidence advancing cell therapy for Alzheimer's disease

Borlongan CV.

Exp Neurol. 2012 Sep;237(1):142-6. doi: 10.1016/j.expneurol.2012.06.024. Epub 2012 Jun 27.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x.

Recruitment methods for United States Alzheimer disease prevention trials

Schneider LS.

J Nutr Health Aging. 2012 Apr;16(4):331-5. doi: 10.1007/s12603-012-0011-6.

Review of drugs for Alzheimer's disease

Sun X, Jin L, Ling P.

Drug Discov Ther. 2012 Dec;6(6):285-90.

Sexuality in institutionalized elderly persons: a systematic review of argument-based ethics literature

Mahieu L, Gastmans C.

Int Psychogeriatr. 2012 Mar;24(3):346-57. doi: 10.1017/S1041610211001542. Epub 2011 Aug 24.

Progress in Alzheimer's disease

Galimberti D, Scarpini E.

J Neurol. 2012 Feb;259(2):201-11. doi: 10.1007/s00415-011-6145-3. Epub 2011 Jun 25.

Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial

Abner EL, Dennis BC, Mathews MJ, Mendiondo MS, Caban-Holt A, Kryscio RJ, Schmitt FA; PREADViSE Investigators; Crowley JJ; SELECT Investigators.

Trials. 2012 Nov 20;13:217. doi: 10.1186/1745-6215-13-217.

Current status of vaccination therapies in Alzheimer's disease

Karran E.

J Neurochem. 2012 Dec;123(5):647-51. doi: 10.1111/jnc.12009. Epub 2012 Oct 11.